2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Helen R Murphy

doi:10.1111/dme.14576

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Helen R Murphy

Research output: Contribution to journal › Comment/debate › peer-review

10 Citations (Scopus)

36 Downloads (Pure)

Abstract

In December 2020, the National Institute for Health and Care Excellence (NICE) reviewed the evidence and updated their recommendations on intermittently scanned (commonly known as Flash) and Continuous Glucose Monitoring (CGM) during pregnancy for women with type 1 diabetes (1). The NICE guidelines now recommend offering CGM to all pregnant women with type 1 diabetes to help them meet their pregnancy glucose targets and improve neonatal outcomes. Their evidence review, based on the CONCEPTT randomised trial (2) and a Swedish observational study (3) found that, compared to capillary glucose monitoring, CGM resulted in more women achieving their blood glucose targets, fewer caesarean sections and fewer neonatal intensive care admissions.

Original language	English
Article number	e14576
Journal	Diabetic Medicine
Volume	38
Issue number	6
Early online date	1 Apr 2021
DOIs	https://doi.org/10.1111/dme.14576
Publication status	Published - Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dme.14576Licence: CC BY-NC

Published_VersionFinal published version, 1.25 MBLicence: CC BY-NC

https://onlinelibrary.wiley.com/doi/10.1111/dme.14576Licence: CC BY-NC

Cite this

@article{68ea056761d048da8d64ff19f7c1c7a9,

title = "2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes",

abstract = "In December 2020, the National Institute for Health and Care Excellence (NICE) reviewed the evidence and updated their recommendations on intermittently scanned (commonly known as Flash) and Continuous Glucose Monitoring (CGM) during pregnancy for women with type 1 diabetes (1). The NICE guidelines now recommend offering CGM to all pregnant women with type 1 diabetes to help them meet their pregnancy glucose targets and improve neonatal outcomes. Their evidence review, based on the CONCEPTT randomised trial (2) and a Swedish observational study (3) found that, compared to capillary glucose monitoring, CGM resulted in more women achieving their blood glucose targets, fewer caesarean sections and fewer neonatal intensive care admissions.",

author = "Murphy, {Helen R}",

year = "2021",

month = jun,

doi = "10.1111/dme.14576",

language = "English",

volume = "38",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - 2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

AU - Murphy, Helen R

PY - 2021/6

Y1 - 2021/6

N2 - In December 2020, the National Institute for Health and Care Excellence (NICE) reviewed the evidence and updated their recommendations on intermittently scanned (commonly known as Flash) and Continuous Glucose Monitoring (CGM) during pregnancy for women with type 1 diabetes (1). The NICE guidelines now recommend offering CGM to all pregnant women with type 1 diabetes to help them meet their pregnancy glucose targets and improve neonatal outcomes. Their evidence review, based on the CONCEPTT randomised trial (2) and a Swedish observational study (3) found that, compared to capillary glucose monitoring, CGM resulted in more women achieving their blood glucose targets, fewer caesarean sections and fewer neonatal intensive care admissions.

AB - In December 2020, the National Institute for Health and Care Excellence (NICE) reviewed the evidence and updated their recommendations on intermittently scanned (commonly known as Flash) and Continuous Glucose Monitoring (CGM) during pregnancy for women with type 1 diabetes (1). The NICE guidelines now recommend offering CGM to all pregnant women with type 1 diabetes to help them meet their pregnancy glucose targets and improve neonatal outcomes. Their evidence review, based on the CONCEPTT randomised trial (2) and a Swedish observational study (3) found that, compared to capillary glucose monitoring, CGM resulted in more women achieving their blood glucose targets, fewer caesarean sections and fewer neonatal intensive care admissions.

UR - http://www.scopus.com/inward/record.url?scp=85104126745&partnerID=8YFLogxK

U2 - 10.1111/dme.14576

DO - 10.1111/dme.14576

M3 - Comment/debate

VL - 38

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 6

M1 - e14576

ER -

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Abstract

UN SDGs

Access to Document

Other files and links

Cite this